Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

3SBio and US-based Selecta Forge Deal on Gout Treatment

publication date: Jun 17, 2014
3SBio of China out-licensed rights for its gout treatment to Selecta Biosciences, a US clinical stage company that develops antigen-specific immune treatments. Selecta intends to apply its Synthetic Vaccine Particle (SVP) platform to 3SBio’s pegsiticase (Uricase PEG-20). The goal is to refine the original drug so that it does not create an immune response and create drug resistance. Selecta will have rights to pegsiticase and related products in the US and Europe, while 3SBio will retain rights in China and Japan. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital